Eledon Pharmaceuticals Inc

1. 1

   Election of Class III Directors

   ManagementBoard: FOR

   Elect David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson as Class III directors to serve until the 2029 annual meeting.

2. 2

   Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock from 300,000,000 to 450,000,000

   ManagementBoard: FOR

   Amend the Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 450,000,000.

   More detail

   This management proposal asks shareholders to approve an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of Common Stock from 300,000,000 to 450,000,000. Management seeks this approval to provide flexibility to fund operations, obtain financing, support strategic transactions (acquisitions, collaborations), grant equity awards, and implement other corporate actions without the delay and cost of calling a special meeting of stockholders. The board emphasizes the need for authorized shares given the Company’s capital requirements as a clinical-stage biotech with no product revenue and ongoing financing activities. The proxy discloses that a substantial number of shares are already reserved for existing instruments (warrants, pre-funded warrants, convertible preferred, equity plans, and potential ATM sales), and the increase would provide additional room for future issuances. The board acknowledges potential dilution to existing stockholders and also notes potential anti-takeover effects since additional shares could be used defensively, but it represents that there is no current intention to use the amendment to entrench management. The board recommends a vote FOR the amendment, asserting the benefits of flexibility and readiness to pursue financings or strategic opportunities outweigh the risks of dilution. The proposal would be effective upon filing a Certificate of Amendment with the Delaware Secretary of State, and the board retains discretion to abandon the amendment before filing even if approved by shareholders.

3. 3

   Ratification of the Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify Deloitte & Touche LLP as the independent registered public accounting firm for the year ending December 31, 2026.

Upcoming shareholder meetings at Eledon Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Eledon Pharmaceuticals Inc 2026 annual meeting?

Eledon Pharmaceuticals Inc (ELDN) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.

What is the record date for the Eledon Pharmaceuticals Inc 2026 meeting?

The record date for the Eledon Pharmaceuticals Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Eledon Pharmaceuticals Inc's 2026 meeting?

The board is presenting 3 director nominees at the Eledon Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Eledon Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Eledon Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.